The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Discovering New Pathways To Improved Biotherapeutic Treatment Of Snakebite Envenoming.
Funder
National Health and Medical Research Council
Funding Amount
$314,644.00
Summary
Snakebite is a public health emergency affecting up to 5.4 million people a year, causing up to 125,000 deaths. This multidisciplinary project will develop a new generation of medicines for treating snakebites, using innovative design approaches supported by cutting edge science and novel production ideas. Directly focused on improving antivenom effectiveness in the treatment of snakebites in Australia, Africa and Papua New Guinea, the results will make Australia a world leader in this field.
Bioresponsive Porous Silicon For Site Specific Oral Delivery Of Antibodies For The Treatment Of Inflammatory Bowel Disease
Funder
National Health and Medical Research Council
Funding Amount
$318,768.00
Summary
This proposal aims to develop an oral antibody delivery system for treatment of inflammatory bowel disease (IBD) that affects 75000 Australians. The system will be based on porous silicon nanoparticles acting as a container to protect the antibodies, and bioresponsive coatings acting as gates to enable site specific protein delivery at the inflamed site of GI tract. The project not only holds promise for protein delivery for the treatment of IBD but other diseases like diabetes.
Identifying Mechanisms Of Resistance To Novel Hormonal Agents In Patients With Castrate-resistant Prostate Cancer
Funder
National Health and Medical Research Council
Funding Amount
$420,004.00
Summary
I am a medical oncologist focused on prostate cancer, a disease which kills over 3000 Australian men every year. Recent studies have shown that new hormone treatments help men with advanced prostate cancer live longer. Unfortunately, while these drugs are effective when first started, prostate cancers eventually become resistant to them and start growing again. By looking at why these drugs stop working, I hope to find better treatments for Australian men with advanced prostate cancer.
Novel Therapeutic Strategies For Pancreatic Cancer Using Next Generation Sequencing
Funder
National Health and Medical Research Council
Funding Amount
$354,892.00
Summary
Dr David Chang is a surgeon scientist who specialises in the treatment of pancreatic cancer. His research focus is on the development and implementation of novel therapeutic strategies for pancreatic cancer. He aims to achieve this by utilising novel biomarkers that have the ability to forecast prognosis and response to treatments. Ultimately, this will lead to the “individualised” treatment for each patient.
Determining The Clinical Relevance Of Intratumour Heterogeneity In Breast Cancer And Its Relationship To Metastases Formation
Funder
National Health and Medical Research Council
Funding Amount
$314,644.00
Summary
Breast cancer metastasis is generally an incurable disease, yet it is not well-understood. This project aims to understand how cancer metastasises by using a novel and unique approach of analysing multiple regions from matched primary and metastatic tumours from breast cancer patients. Expected outcomes include identifying predictors of treatment resistance and resultant personalised management and therapeutic strategies to improve survival outcomes of breast cancer patients.
Next-generation Glioblastoma Multiforme Therapies Based On Multistage Delivery Nanovectors
Funder
National Health and Medical Research Council
Funding Amount
$314,644.00
Summary
Nanomedicine provides novel therapies with enhanced treatment success and reduced side effects, which improve the patient’s quality of life. Drug delivery systems that are able to treat highly drug-resistant tumours such as glioblastoma multiforme (GBM) are a key target for nanomedicine-based therapies. We will investigate a new GBM treatment by developing a multistage delivery nanovector to selectively carry and release a combination of chemical and physical therapeutics.
The Role Of The Alimentary Microbiome In The Development Of Mucositis
Funder
National Health and Medical Research Council
Funding Amount
$302,123.00
Summary
Mucositis is a debilitating side effect of cancer treatment, which is currently not treatable or preventable, due to a lack of understanding of how mucositis develops. Previous research has shown that microbes are involved in the development of mucositis in animal models. This project will determine if bacteria in the mouth and intestine play a role in the development of mucositis in patients, and if changes are easily detected, to allow for a more 'personalised' approach to manage mucositis.
Toll-like Receptor 2 Signalling As A Potential Therapeutic Target In Gastric Cancer
Funder
National Health and Medical Research Council
Funding Amount
$323,091.00
Summary
Stomach cancer is the fourth most deadly cancer in the world. Stomach cancer is closely linked with inflammation, and we have shown that a key inflammatory molecule, called toll-like receptor 2 (TLR2), can drive the development of stomach cancer. However, this occurs in a non-inflammatory manner. My research aims to understand how TLR2 is involved in the progression of stomach cancer, with the ultimate goal to find an early biomarker of disease, and to develop better therapies.
Targeting The Epithelial-to-mesenchymal Transition In Basal-like Breast Cancers
Funder
National Health and Medical Research Council
Funding Amount
$348,823.00
Summary
Metastasis accounts for over 90% of deaths due to cancer worldwide. I aim to uncover the signals, which drive cancer cells to distant sites leading to metastatic tumour growth. Although the efficacy of current therapeutics is improving, they are unable to counteract tumour spread and relapses that are common with many cancers. My research will focus on understanding the events that lead to metastasis thus enabling us to develop better therapies for aggressive cancers.